[go: up one dir, main page]

GT201600135A - Análogos de cortistatina y síntesis y uso de los mismos - Google Patents

Análogos de cortistatina y síntesis y uso de los mismos

Info

Publication number
GT201600135A
GT201600135A GT201600135A GT201600135A GT201600135A GT 201600135 A GT201600135 A GT 201600135A GT 201600135 A GT201600135 A GT 201600135A GT 201600135 A GT201600135 A GT 201600135A GT 201600135 A GT201600135 A GT 201600135A
Authority
GT
Guatemala
Prior art keywords
cortistatin
synthesis
same
analogs
same analogs
Prior art date
Application number
GT201600135A
Other languages
English (en)
Inventor
D Shair Matthew
Ramharter Juergen
Efrem Pelish Henry
Bor-Jen Liau Brian
Young Ahn Jae
Original Assignee
President And Fellows Of Harvard C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard C filed Critical President And Fellows Of Harvard C
Publication of GT201600135A publication Critical patent/GT201600135A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS ANÁLOGOS DE CORTISTATINA, Y SALES FARMACÉUTICAMENTE ACEPTABLES, SALES DE AMINA CUATERNARIA, Y N-ÓXIDOS DE LOS MISMOS, SINTETIZADOS, EN PARTE, POR AMINACIÓN REDUCTIVA DE UNA CETONA PARA PROPORCIONAR EL PRODUCTO AMINADO, OPCIONALMENTE A TRAVÉS DE UN INTERMEDIO DE IMINA.
GT201600135A 2013-12-24 2016-06-24 Análogos de cortistatina y síntesis y uso de los mismos GT201600135A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US201461993329P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
GT201600135A true GT201600135A (es) 2018-11-27

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600135A GT201600135A (es) 2013-12-24 2016-06-24 Análogos de cortistatina y síntesis y uso de los mismos

Country Status (30)

Country Link
US (3) US9994582B2 (es)
EP (2) EP3087080B1 (es)
JP (2) JP6494631B2 (es)
KR (1) KR20160101162A (es)
CN (2) CN106103452B (es)
AP (1) AP2016009324A0 (es)
AU (2) AU2014369834B2 (es)
BR (1) BR112016014760A2 (es)
CA (1) CA2934819A1 (es)
CL (1) CL2016001631A1 (es)
CR (1) CR20160291A (es)
DO (1) DOP2016000158A (es)
EA (2) EA030907B1 (es)
EC (1) ECSP16062174A (es)
ES (1) ES2709480T3 (es)
GT (1) GT201600135A (es)
IL (1) IL246390A0 (es)
MD (1) MD20160089A2 (es)
MX (1) MX361652B (es)
MY (1) MY180383A (es)
NI (1) NI201600089A (es)
PE (1) PE20161405A1 (es)
PH (1) PH12016501258A1 (es)
RU (1) RU2016126503A (es)
SA (1) SA516371410B1 (es)
SG (2) SG11201605178WA (es)
SV (1) SV2016005234A (es)
TN (1) TN2016000240A1 (es)
WO (1) WO2015100420A1 (es)
ZA (1) ZA201603894B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6494631B2 (ja) 2013-12-24 2019-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ コルチスタチン類縁体並びにその合成及び使用
JP6466461B2 (ja) 2014-02-03 2019-02-06 ヴァイティー ファーマシューティカルズ,インコーポレイテッド Rorガンマのジヒドロピロロピリジン阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
RU2017142394A (ru) * 2015-05-08 2019-06-10 Президент Энд Феллоус Оф Гарвард Колледж Целевой отбор пациентов для лечения производными кортистатина
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
JP6914257B2 (ja) 2015-11-20 2021-08-04 ヴァイティー ファーマシューティカルズ,エルエルシー Ror−ガンマのモジュレーター
WO2017112823A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Targeted selection of patients for treatment with specific cortistatin derivatives
EP3394072A4 (en) * 2015-12-23 2019-05-29 President and Fellows of Harvard College Cortistatin analogs and uses thereof
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
KR20180110134A (ko) * 2016-02-19 2018-10-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
ES3004107T3 (en) 2017-01-30 2025-03-11 Univ Kyoto Novel compound, and method for producing regulatory t cells
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
EP4065111A4 (en) 2019-11-26 2023-09-20 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of cdk8 and cdk19
MX2024003619A (es) 2021-09-27 2024-04-19 Univ Kyoto Metodo para producir celulas t.
KR20240130083A (ko) 2021-11-24 2024-08-28 레그셀 가부시키가이샤 T세포 관련 질환을 치료 또는 예방하기 위한 의약 조성물
WO2023095801A1 (ja) 2021-11-24 2023-06-01 レグセル株式会社 ヒト誘導性制御性t細胞およびその作製方法
US20250230411A1 (en) 2022-03-23 2025-07-17 Kyoto University Method for producing regulatory t cells
KR20250077533A (ko) 2022-09-26 2025-05-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T 세포 제조 방법
JPWO2024071039A1 (es) 2022-09-26 2024-04-04
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
KR20020028876A (ko) 1999-04-30 2002-04-17 추후제출 스테로이드 유도체
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU781524B2 (en) 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003512474A (ja) 1999-10-25 2003-04-02 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症の治療処置
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
US20030187076A1 (en) 2002-01-30 2003-10-02 Agoston Gregory E. Non-steroidal analogs of 2-methoxyestradiol
ATE433457T1 (de) 2002-12-24 2009-06-15 Univ British Columbia Angiogen-wirkende trisulfat steroide und deren verwendung
ES2339450T3 (es) 2003-03-24 2010-05-20 Sterix Limited Derivados de estrogenos como inhibidores de esteroide sulfatasa.
EP1633367A2 (en) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
US7745644B2 (en) * 2003-07-24 2010-06-29 Merck Sharp & Dohme Corp. Antibiotic compounds
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
BRPI0607523A2 (pt) 2005-03-02 2009-09-08 Univ Maryland compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
CN101400690A (zh) 2006-01-09 2009-04-01 英国技术集团国际有限公司 低氧诱导因子-1调节剂和相关用途
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
EP2029575B1 (en) * 2006-05-09 2014-10-22 Merck Sharp & Dohme Corp. Substituted spirocyclic cgrp receptor antagonists
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
CN101600711A (zh) 2006-12-22 2009-12-09 工业研究有限公司 核苷酶和磷酸化酶抑制剂的氮杂环丁烷类似物
CN101675054B (zh) 2007-03-07 2014-05-14 无限发现股份有限公司 环杷明内酰胺类似物及其使用方法
WO2009046314A2 (en) * 2007-10-04 2009-04-09 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
WO2009137335A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute Synthesis of (+) corstistatin a and related compounds
US20110190323A1 (en) * 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
WO2010123545A2 (en) 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
RU2012152352A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
US8791263B2 (en) 2010-09-17 2014-07-29 Osaka University Cortistatin A analog and use thereof
WO2012096934A2 (en) 2011-01-10 2012-07-19 The Scripps Research Institute Inhibitors of retroviral replication
BR112014019052A8 (pt) 2012-02-02 2017-07-11 Senex Biotechnology Inc Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
EP2961409A1 (en) 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
US20160208246A1 (en) 2013-06-10 2016-07-21 Yeda Research And Development Co. Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
US12297294B2 (en) 2013-09-18 2025-05-13 Bcn Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
JP6494631B2 (ja) * 2013-12-24 2019-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ コルチスタチン類縁体並びにその合成及び使用

Also Published As

Publication number Publication date
CN106103452A (zh) 2016-11-09
IL246390A0 (en) 2016-08-31
SA516371410B1 (ar) 2019-02-13
ZA201603894B (en) 2018-08-29
CN110183461A (zh) 2019-08-30
AU2014369834B2 (en) 2018-12-20
US20170029435A1 (en) 2017-02-02
EA201891279A1 (ru) 2019-01-31
MX361652B (es) 2018-12-13
TN2016000240A1 (en) 2017-10-06
KR20160101162A (ko) 2016-08-24
JP2017509586A (ja) 2017-04-06
CL2016001631A1 (es) 2017-02-24
RU2016126503A3 (es) 2018-07-17
EP3087080B1 (en) 2018-11-28
BR112016014760A2 (pt) 2017-12-12
JP6494631B2 (ja) 2019-04-03
US10508121B2 (en) 2019-12-17
RU2016126503A (ru) 2018-01-30
DOP2016000158A (es) 2016-10-16
AU2014369834A1 (en) 2016-06-23
US20180319814A1 (en) 2018-11-08
SG11201605178WA (en) 2016-07-28
SG10201808151RA (en) 2018-10-30
NI201600089A (es) 2016-08-18
MY180383A (en) 2020-11-28
PE20161405A1 (es) 2017-01-18
EP3087080A1 (en) 2016-11-02
US10273241B2 (en) 2019-04-30
CN106103452B (zh) 2019-05-21
AU2019201888A1 (en) 2019-04-11
MD20160089A2 (ro) 2016-12-31
MX2016008436A (es) 2016-12-16
WO2015100420A1 (en) 2015-07-02
ES2709480T3 (es) 2019-04-16
US20190185484A1 (en) 2019-06-20
CR20160291A (es) 2017-02-24
AP2016009324A0 (en) 2016-07-31
JP2019108367A (ja) 2019-07-04
EP3505521A1 (en) 2019-07-03
ECSP16062174A (es) 2018-12-31
SV2016005234A (es) 2018-12-14
US9994582B2 (en) 2018-06-12
PH12016501258A1 (en) 2016-08-15
EA201691167A1 (ru) 2016-11-30
CA2934819A1 (en) 2015-07-02
EA030907B1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
GT201600135A (es) Análogos de cortistatina y síntesis y uso de los mismos
ECSP18092481A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
MX2017014108A (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
DOP2014000203A (es) Compuestos de heterociclilo
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
CR20150371A (es) Inhibidores de prmt5 y sus usos
MX2016004742A (es) Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.
MX386584B (es) Composiciones de liberación retardada de linaclotida.
ECSP14013215A (es) Compuestos novedosos
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
HUE053379T2 (hu) Génmódosított imin-reduktázok és eljárások keton és amin vegyületek reduktív aminálására
ECSP17069696A (es) Compuestos novedosos
BR112016007581A2 (pt) pigmentos à base de compostos de bismuto
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
BR112016005380A2 (pt) Processo aprimorado para preparar fórmula infantil utilizando um misturador estático
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
GT201500292A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
AR099132A1 (es) Colorante-polímero
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
BR112015022509A2 (pt) forma cristalina de cis-(e)-4-(3-fluorofenil)-2',3',4',9'-tetra-hidro-n,n-dimetil-2'-(1-oxo-3-fenil-2-propenil)-espiro[ciclohexano-1,1'[1h]-pirido[3,4-b]indol]-4-amina cristalina
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino